Bial - Portela C S.A.: Pulmonary Arterial Hypertension trials

The registry lists 12 Pulmonary Arterial Hypertension studies with Bial - Portela C S.A. as lead sponsor. 0 are open to participants now and 1 have results posted.

Phase 1 10Phase 2 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)CompletedNCT04316143Phase 2Results posted
• Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and FurosemideCompletedNCT07173738Phase 1
• Safety and Efficacy of BIA 5-1058 in PAHCompletedNCT06009185Phase 2
• Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of SildenafilCompletedNCT04994860Phase 1
• Effect of BIA 5-1058 400 mg on Warfarin PharmacokineticsCompletedNCT04994119Phase 1
• Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of BosentanCompletedNCT04991207Phase 1
• Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058TerminatedNCT04991194Phase 1
• Absorption, Distribution, Metabolism and Excretion of BIA 5-1058CompletedNCT04991181Phase 1
• Effect of Food on BIA 5-1058CompletedNCT04991155Phase 1
• Effect of BIA 5-1058 on the Steady State Pharmacokinetics of TreprostinilCompletedNCT04675944Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058CompletedNCT03708146Phase 1
• Effect of BIA 5 1058 on Cardiac RepolarizationCompletedNCT03489005Phase 1